Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

Income Statement

Follow revenue through to earnings.

Revenue

$90,000.00

FY 2025 · Annual

Operating Income

-$36.25M

FY 2025 · Annual

Net Income

-$33.89M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14M1.03M81K090K
Cost of Revenue524K00811K0
Gross Profit620K1.03M81K(811K)90K
Gross Margin54.2%100.0%100.0%—100.0%
Research & Development17.51M23.14M38.67M30.05M21.12M
Selling, General & Admin8.08M12M13.33M12.08M15.21M
Operating Expenses25.58M35.13M52M41.31M36.34M
Depreciation & Amortization524K699K790K811K821K
EBITDA(24.25M)(32.32M)(48.03M)(37.43M)(33.07M)
EBITDA Margin-2119.8%-3137.7%-59293.8%—-36740.0%
Operating Income(24.96M)(34.1M)(51.92M)(42.12M)(36.25M)
Operating Margin-2182.2%-3311.1%-64098.8%—-40274.4%
Interest Income190K1.09M3.1M3.88M2.36M
Interest Expense00000
Other Income / Expenses190K1.09M3.1M3.88M2.36M
Income Before Tax(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Pre-Tax Margin-2165.6%-3205.5%-60269.1%—-37652.2%
Income Tax Expense00000
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Net Margin-2165.6%-3205.5%-60269.1%—-37652.2%
EPS (Basic)(1.20)(1.37)(1.83)(1.27)(1.09)
EPS (Diluted)(1.20)(1.37)(1.83)(1.27)(1.09)
Weighted Avg Shares20.57M24.14M26.6M30.07M31.2M
Weighted Avg Shares (Diluted)20.57M24.14M26.6M30.07M31.2M

ATNM Earnings Waterfall · TTM

AMEX:ATNM · Revenue to Net Income

Key Ratios

EPS$0.36
Gross Margin50.0%
Net Margin-1405.3%
P/E Ratio-1.3
P/S Ratio138.9

Analysis

$35.1M of revenue converted into $11.3M of net income for the selected period. Gross margin is 50.0% and net margin is -1405.3%, showing how much revenue survives after costs and taxes. EPS is $0.36, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 16, 2026
3Initial statement of beneficial ownershipOct 16, 2026
8-KCurrent reportOct 15, 2026
DEF 14ADEF 14A filingOct 15, 2026
ARSARS filingOct 15, 2026

How much revenue does ATNM generate?

Actinium Pharmaceuticals, Inc. (ATNM) reported $90,000.00 of revenue in fiscal 2025.

Is ATNM profitable?

Actinium Pharmaceuticals, Inc. (ATNM) reported -$33.89M of net income, with a net margin of -37652.2%.